Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lithium augmentation in refractory depression.

C L Katona1

  • 1Department of Psychiatry, University College and Middlesex School of Medicine, Middlesex Hospital, London, UK.

Psychiatric Developments
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A double-blind controlled comparison of fluoxetine and lofepramine in major depressive illness.

Journal of psychopharmacology (Oxford, England)·2012
Same author

Sulpiride-induced tardive dyskinesia in a person with Gilles de la Tourette syndrome.

Journal of psychopharmacology (Oxford, England)·2012
Same author

Corticotropin-releasing factor immunoreactivity in post-mortem brain from depressed suicides.

Journal of psychopharmacology (Oxford, England)·2011
Same author

Psychotropics and drug interactions in the elderly patient.

International journal of geriatric psychiatry·2001
Same author

Altered brain protein kinase C in depression: a post-mortem study.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2000
Same author

Three years survival in patients with a clinical diagnosis of dementia with Lewy bodies.

International journal of geriatric psychiatry·2000

Lithium salt augmentation shows promise for treating refractory depression when standard antidepressants fail. Clinical trials suggest a 60% response rate, potentially involving enhanced neurotransmission.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Refractory depression poses a significant clinical challenge.
  • Conventional antidepressant treatments are often insufficient for some patients.

Purpose of the Study:

  • To evaluate the efficacy of lithium augmentation in patients with treatment-resistant depression.
  • To explore potential mechanisms underlying lithium's augmentatory effects.

Main Methods:

  • Review of evidence from open and placebo-controlled clinical trials.
  • Analysis of case reports on lithium augmentation in extremely refractory depression.

Main Results:

  • Lithium augmentation demonstrates a promising response rate of approximately 60% in refractory depression.

Related Experiment Videos

  • Evidence suggests lithium's action may involve enhanced serotonergic neurotransmission.

    • Conclusions:

    • Lithium augmentation is a viable strategy for managing treatment-resistant depression.
    • Further research is needed to identify responders and elucidate precise neurobiological mechanisms.